President and CEO, Omega Therapeutics
Mahesh Karande is deeply experienced in running biopharma businesses across discovery, preclinical development, clinical development, commercialization and product life cycle management stages. His breadth of therapeutic experience spans cardiovascular and metabolic, oncology, neurosciences, ophthalmology, antibiotics, pain, respiratory and rare and genetic diseases as well as drug and device combinations. He has strong leadership, operational and business-building experiences combined with a global work history spanning the U.S., Europe, Asia and Africa. Prior to taking the helm at Omega, Mr. Karande was President and CEO of Macrolide Pharmaceuticals, a company he took from discovery into early development. Earlier, Mr. Karande spent several years at Novartis in senior leadership roles: VP and Head of US Oncology for solid tumors, President of Novartis Africa and President of Novartis Egypt. He worked for McKinsey & Company prior to joining the bio-pharmaceutical industry. Mr. Karande has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology where he completed his M.S. in engineering and the University of Bombay where he completed undergraduate studies in engineering.